-
1.发明公开Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination 有权在体外和体内的人抗原激活的细胞的T细胞刺激能力改善以及它们用于疫苗接种使用
公开(公告)号：EP2700708A2
公开(公告)日：2014-02-26
申请号：EP13181345.3
申请日：2013-08-22
IPC分类号： C12N5/0784
CPC分类号： A61K39/39 , A61K39/0011 , A61K2039/5154 , A61K2039/5156 , A61K2039/5158 , A61K2039/53 , A61K2039/54 , A61K2039/55516 , A61K2039/57 , C12N5/0639 , C12N2510/00 , Y02A50/386 , Y02A50/403 , Y02A50/407 , Y02A50/484
摘要： With the current invention, we provide new methods of in vitro or in vivo enhancing the T-cell stimulatory capacity of human DCs and the use thereof in cancer vaccination. The method comprises the introduction of different molecular adjuvants to human DCs by contacting or modifying them with mRNA or DNA molecule(s) encoding CD40L, and CD70 or constitutively active TLR4 (caTLR4).
摘要翻译： 与当前的发明中，我们提供在体外或在体内促进人DCs的T细胞刺激能力和在癌症疫苗中的用途的新方法。 该方法包括通过接触或用编码CD40L和CD70或组成型活性TLR4（caTLR4）mRNA或DNA分子（多个）修改它们引入不同的分子佐剂以人DC的。
-
公开(公告)号：EP2700708B1
公开(公告)日：2017-08-02
申请号：EP13181345.3
申请日：2013-08-22
IPC分类号： C12N5/0784
CPC分类号： A61K39/39 , A61K39/0011 , A61K2039/5154 , A61K2039/5156 , A61K2039/5158 , A61K2039/53 , A61K2039/54 , A61K2039/55516 , A61K2039/57 , C12N5/0639 , C12N2510/00 , Y02A50/386 , Y02A50/403 , Y02A50/407 , Y02A50/484
摘要： With the current invention, we provide new methods of enhancing the T-cell stimulatory capacity of human dendritic cells (DCs) and their use in cancer vaccination. The method comprises the introduction of different molecular adjuvants to human DCs through transfection with at least two mRNA or DNA molecules encoding markers selected from the group of: CD40L, CD70, constitutively active TLR4 (caTLR4), IL-12p70, EL-selectin, CCR7 and/or 4-1 BBL; or in combination with inhibition of SOCS, A20, PD-L1 and/or STAT3 expression, for example through siRNA transfection. We could show a clear increase in the immunostimulatory capacity of DCs obtained in this way, enabling them to elicit an unexpectedly high T-cell immune response in vitro. Introduction of at least two of the above molecules, in combination with a tumor-specific antigen enables the DCs to elicit a significant host-mediated T-cell immune response in vivo against the tumor antigen and thus makes them very attractive in the manufacturing of anti-cancer vaccines.
-
3.发明公开Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination 有权提高体外和体内人抗原呈递细胞的T细胞刺激能力及其在疫苗接种中的应用
公开(公告)号：EP2700708A3
公开(公告)日：2014-04-16
申请号：EP13181345.3
申请日：2013-08-22
IPC分类号： C12N5/0784
CPC分类号： A61K39/39 , A61K39/0011 , A61K2039/5154 , A61K2039/5156 , A61K2039/5158 , A61K2039/53 , A61K2039/54 , A61K2039/55516 , A61K2039/57 , C12N5/0639 , C12N2510/00 , Y02A50/386 , Y02A50/403 , Y02A50/407 , Y02A50/484
摘要： With the current invention, we provide new methods of in vitro or in vivo enhancing the T-cell stimulatory capacity of human DCs and the use thereof in cancer vaccination. The method comprises the introduction of different molecular adjuvants to human DCs by contacting or modifying them with mRNA or DNA molecule(s) encoding CD40L, and CD70 or constitutively active TLR4 (caTLR4).
摘要翻译： 利用本发明，我们提供了体外或体内增强人DC的T细胞刺激能力的新方法及其在癌症疫苗接种中的用途。 该方法包括通过将它们与编码CD40L和CD70或组成性活化的TLR4（caTLR4）的mRNA或DNA分子接触或修饰它们而将不同的分子佐剂引入人DC。
-
-
搜索结果
3 条记录 (耗时 0.012 秒)
